765: Karan D. Prostate immunotherapy: should all guns be aimed at the
prostate-specific antigen? Immunotherapy. 2013 Sep;5(9):907-10. doi:
10.2217/imt.13.83. Review. PubMed PMID: 23998723.


766: Karan D, Holzbeierlein JM, Van Veldhuizen P, Thrasher JB. Cancer
immunotherapy: a paradigm shift for prostate cancer treatment. Nat Rev Urol. 2012
May 29;9(7):376-85. doi: 10.1038/nrurol.2012.106. Review. PubMed PMID: 22641164.


767: Karan D, Van Veldhuizen P. Combination immunotherapy with prostate GVAX and 
ipilimumab: safety and toxicity. Immunotherapy. 2012 Jun;4(6):577-80. doi:
10.2217/imt.12.53. PubMed PMID: 22788125.


768: Karan D, Dubey S, Van Veldhuizen P, Holzbeierlein JM, Tawfik O, Thrasher JB.
Dual antigen target-based immunotherapy for prostate cancer eliminates the growth
of established tumors in mice. Immunotherapy. 2011 Jun;3(6):735-46. doi:
10.2217/imt.11.59. PubMed PMID: 21668311.


769: Karan D, Thrasher JB, Lubaroff D. Prostate cancer: genes, environment,
immunity and the use of immunotherapy. Prostate Cancer Prostatic Dis.
2008;11(3):230-6. doi: 10.1038/pcan.2008.3. Epub 2008 Feb 19. Review. PubMed
PMID: 18283297.